Homocysteine as a cardiovascular marker and risk factor;Homocystein als kardiovaskulärer marker und risikofaktor

Clinical Research in Cardiology

Volumn 95, Issue SUPPL. 6, 2006, Pages

  Pietrzik, K ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Folic acid; Homocysteine; Homocysteinemia

Indexed keywords

HOMOCYSTEINE;

AUSTRIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; GERMANY; HUMAN; MEDICAL RESEARCH; REVIEW; RISK FACTOR; SWITZERLAND;

CAUSE OF DEATH; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MYOCARDIAL INFARCTION; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; VITAMIN B 12; VITAMIN B 6;

EID: 33749410773     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-006-1806-4     Document Type: Review

References (15)

1. Botto LD, Friedman JM, Yang Q (2004) Vortrag anlässlich der American Heart Association's 44th Annual Conference on Cardiovascular Disease Epidemiology and Prevention. San Francisco (USA)
2. Boushey CJ, Beresford SA, Omenn GS et al (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274:049
3. Lange H, Suryapranata H, De Luca G et al (2004) Folate Therapy and In-Stent Restenosis after Coronary Stenting. N Engl J Med 350:2673
4. Malinow MR, Ducimetiereb P, Lucc G et al (1996) Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis 126:27
5. Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, Gluckman RA, Block PC, Upson BM (1998) Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 338(15):1009-1115
6. Nygård O, Nordrehaug JE, Refsum H et al (1997) Plasma Homocysteine Levels and Mortality in Patients with Coronary Artery Disease. N Engl J Med 337:230
7. Peterson JC, Spence JD (1998) Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet 351:263
8. Rothman 1986
9. Schnyder G, Roffi M, Pin R et al (2001) Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine Levels. N Engl J Med 345:1593
10. Stampfer MJ, Malinow MR, Willett WC et al (1992) A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268:877
11. Stanger O, Dierkes J, Fowler B, Geisel J, Herrmann W, Pietrzik K, Weger M (2003) Konsensuspapier der D.A.CH.-Liga Homocystein über den rationellen klinischen Umgang mit Homocystein, Folsäure und B-Vitaminen bei kardiovaskulären und thrombotischen Erkrankungen - Richtlinen und Empfehlungen. Journal für Kardiologie 10(5):190-199
12. Stanger O, Herrmann W, Pietrzik K et al (2004) Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic disease. Z Kardiol 93:439
13. Stanger O, Lange H (2004) Folate Therapy and In-Stent Restenosis. N Engl J Med 351:1259
14. Toole JF, Malinow MR, Chambless LE et al (2004) Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. JAMA 291:565
15. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, Friedman JM (2006) Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 113:1335